The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and around us has been limited by technology and the difficulty of culturing most microbes in a lab. Biosortia Microbiomics has developed a platform for finding, amplifying, and screening microbes as a potential source of novel, small molecule drugs. We spoke to Ross Youngs, CEO and founder of Biosortia, about the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.
A Venture Capitalist’s View of the Current Biotech Landscape
Realizing the Therapeutic Potential of Cytokines by Making them Context Dependent
Targeting Cancer and Autoimmune Conditions with Donor-Derived EBV T Cells
Reprogramming the Tumor Microenviroment to Activate an Immune Response
Making Safer and More Effective Vaccines with Targeted mRNA
Addressing a Global Need with RNA Vaccines and Immunotherapies
Targeting Bacteria in Chronic Diseases
Targeting Solid Tumors with Off-The-Shelf CAR T Therapies
Reimagining the Development of Immunotherapies with a Venture Studio
Repairing the Body with Advanced Cell Therapies
Achieving Precision with AI Pathology
Inducing Potent and Durable T Cell Responses to Fight Disease
Developing Immunotherapies that Target the Drivers of Cancer
Using Phase 0 Trials to Bring Precision Medicine to Treating Brain Tumors
Restoring Feeling and Function to Damaged Nerves
Enlisting Vaccines in the Fight Against Chronic Diseases
Extending the Reach of Protein Degradation Therapies
Growing the Bioeconomy
Developing Targeted Therapies to Address Resistance in Cancer
It Takes a Village
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
Speaking of Psychology